Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II CAR-T cell and combination immunotherapy study in stage III/IV colorectal cancer
ChiCTR1900024824Phase 2Recruiting
- Sponsor
- Peking University Shougang Hospital
- Start
- Jul 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of LV20.19 CAR-T in colorectal cancer (CRC) (2 arms), sponsored by Peking University Shougang Hospital. Primary endpoints: Tumor imaging, Interleukin-6 and 3 more. Started Jul 2019; status: recruiting.
02
Drugs
LV20.19 CAR-T
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1900024824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024824.